Compare Moderna, Inc. (MRNA) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Rocket Lab USA Inc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Rocket Lab USA Inc trades at $68.21 (market cap $43.74B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Rocket Lab USA Inc for 29 Days on average.
| MRNA | RKLB | |
|---|---|---|
Market Cap | $78.65B | $43.74B |
Volume | 37,373,437 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $203.46 | $150.23 |
52-Week Low | $22.36 | $39.48 |
Typical Hold Time | 59 Days | 29 Days |
Enterprise Value | $74.80B | $41.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Rocket Lab (RKLB) trades at $68.21, down 5.16% today, amid a bearish technical signal despite recent positive business developments. The company secured its largest-ever commercial Electron deal with Synspective for 20 launches, boosting its backlog past 100 missions. However, financials show negative profitability with a net income margin of -21.51% and elevated valuation ratios including P/S of 51.96. Technical indicators show bearish momentum with key support at $64.
The outlook remains mixed with strong analyst bullishness (76% buy ratings, $107 consensus target) contrasting with fundamental challenges. Investment opportunity lies in execution of the growing launch backlog and Neutron rocket development, while risks include sustained losses, SpaceX competition, and high valuation multiples requiring significant future growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
